Coming October 29: SITC releases its late-breaking abstract titles. We’ll add their presenting authors’ institutions to this guide once they’re out.

Synthekine at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

Synthekine brings 2 presentations to SITC 2026 in Phoenix. Its program centres on STK-012, an engineered form of IL-2 that preferentially stimulates antigen-activated CD8 T cells. It reports that this approach avoids capillary leak syndrome and strengthens the anti-tumor effect of bispecific antibodies targeting PD-1 and VEGF.

Organization	SITC 2026 Attendance
Synthekine Menlo Park, CA
synthekine.com Biotech Develops engineered cytokine therapeutics for cancer and other diseases.	Poster Fri Nov 6 12:15–1:45pm 5:30–7pm Preferential stimulation of antigen activated CD25+ CD8 T cells with STK-012, an α/β biased IL-2, avoids capillary leak syndrome and enhances anti-tumor immunity Exhibition Halls 4-6 · Poster 1041 New agents Talk Sun Nov 8 12:00pm–12:10pm Part of Session 303: COOPERATIVE BINDING: The bi-specific VEGF/PD(L)-1 Inhibitor Approach to cancer immunotherapy: Savior or Pretender? STK-012, a first-in-class α/β IL-2 receptor biased partial agonist enhances the anti-tumor efficacy of bispecific PD-1/VEGF-targeting antibodies Hall A New agents · Clinical

Organization

SITC 2026 Attendance

Synthekine

Menlo Park, CA

synthekine.com

Biotech

Develops engineered cytokine therapeutics for cancer and other diseases.

Poster

Fri Nov 6
12:15–1:45pm
5:30–7pm

Preferential stimulation of antigen activated CD25+ CD8 T cells with STK-012, an α/β biased IL-2, avoids capillary leak syndrome and enhances anti-tumor immunity

Exhibition Halls 4-6 · Poster 1041

New agents